BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis - PubMed (original) (raw)
. 2005 Sep 15;65(1):35-43.
doi: 10.1002/pros.20255.
Affiliations
- PMID: 15800936
- DOI: 10.1002/pros.20255
BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis
Daniel R McCulloch et al. Prostate. 2005.
Abstract
Background: Androgen-dependent prostate cancer (PrCa) xenograft models are required to study PrCa biology in the clinically relevant in vivo environment.
Methods: Human PrCa tissue from a femoral bone metastasis biopsy (BM18) was grown and passaged subcutaneously through male severe combined immune-deficient (SCID) mice. Human mitochondria (hMt), prostate specific antigen (PSA), androgen receptor (AR), cytokeratin-18 (CK-18), pan-cytokeratin, and high molecular weight-cytokeratin (HMW-CK) were assessed using immunohistochemistry (IHC). Surgical castration was performed to examine androgen dependence. Serum was collected pre- and post-castration for monitoring of PSA levels.
Results: BM18 stained positively for hMt, PSA, AR, CK-18, pan keratin, and negatively for HMW-CK, consistent with the staining observed in the original patient material. Androgen-deprivation induced tumor regression in 10/10 castrated male SCID mice. Serum PSA levels positively correlated with BM18 tumor size.
Conclusions: BM18 expresses PSA and AR, and rapidly regresses in response to androgen withdrawal. This provides a new clinically significant PrCa model for the study of androgen-dependent growth.
Similar articles
- Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Jongsma J, et al. Cancer Res. 2000 Feb 1;60(3):741-8. Cancer Res. 2000. PMID: 10676662 - A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW. Matsubara S, et al. Cancer Res. 2001 Aug 15;61(16):6012-9. Cancer Res. 2001. PMID: 11507044 - Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU, Weigel NL. Agoulnik IU, et al. J Cell Biochem. 2006 Oct 1;99(2):362-72. doi: 10.1002/jcb.20811. J Cell Biochem. 2006. PMID: 16619264 Review. - Prognostic value of serum markers for prostate cancer.
Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Stenman UH, et al. Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review.
Cited by
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.
Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A. Corres-Mendizabal J, et al. Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005. Epub 2024 Jul 23. Trends Cancer. 2024. PMID: 39048488 Free PMC article. Review. - Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.
Thomas PB, Alinezhad S, Joshi A, Sweeney K, Tse BWC, Tevz G, McPherson S, Nelson CC, Williams ED, Vela I. Thomas PB, et al. Curr Oncol. 2023 Oct 24;30(11):9437-9447. doi: 10.3390/curroncol30110683. Curr Oncol. 2023. PMID: 37999103 Free PMC article. - hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
Adams MN, Croft LV, Urquhart A, Saleem MAM, Rockstroh A, Duijf PHG, Thomas PB, Ferguson GP, Najib IM, Shah ET, Bolderson E, Nagaraj S, Williams ED, Nelson CC, O'Byrne KJ, Richard DJ. Adams MN, et al. Prostate. 2023 May;83(7):628-640. doi: 10.1002/pros.24496. Epub 2023 Feb 22. Prostate. 2023. PMID: 36811381 Free PMC article. - The future of patient-derived xenografts in prostate cancer research.
Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. Lawrence MG, et al. Nat Rev Urol. 2023 Jun;20(6):371-384. doi: 10.1038/s41585-022-00706-x. Epub 2023 Jan 17. Nat Rev Urol. 2023. PMID: 36650259 Free PMC article. Review. - Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.
Hassan S, Blick T, Wood J, Thompson EW, Williams ED. Hassan S, et al. Front Cell Dev Biol. 2022 Apr 13;10:858013. doi: 10.3389/fcell.2022.858013. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35493092 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous